| 股东类型 比例 | | | 比例 | | | | --- | --- | --- | --- | --- | --- | | 票数 票数 | | 比例（%） | 票数 | | | | （%） | | | | （%） | | | 普通股 29,470,070 0 | 97.0623 | 891,937 | 2.9377 | 0.0000 | | | （二） 涉及重大事项，应说明 | | 5%以下股东的表决情况 | | | | | 议 | 同意 | | 反对 | 弃权 | | | 案 | | | | | | | 议案名称 | | | | | 比例 | | 序 票数 比例（%） | | 比例（%） 票数 | | | 票数 | | （%） | | | | | | | 号 | | | | | | | 《 关 于 公 司 2024 | | | | | | | 案的议案》 | | | | | | | 《关于公司续聘 | | | | | | | 构的议案》 | | | | | | | 《关于公司董事 | | | | | | | 案的议案》 | | | | | | | 《关于公司监事 | | | | | | | 案的议案》 ...

广东信达律师事务所 股东大会 法律意见书 深圳市福田区益田路 6001 号太平金融大厦 11、12 楼 邮政编码：518038 电话(Tel)：(0755)88265288 传真(Fax) ：(0755) 83265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：www.sundiallawfirm.com 广东信达律师事务所 关于北京凯因科技股份有限公司 法律意见书 信达科会字2025第 025 号 致：北京凯因科技股份有限公司 广东信达律师事务所（以下简称"信达"）接受北京凯因科技股份有限公司 （下称"贵公司"）的委托，指派律师参加了贵公司 2024 年年度股东大会（下 称"本次股东大会"），并进行了必要的验证工作。 信达律师根据《中华人民共和国公司法》（下称"《公司法》"）、《上市 公司股东会规则》（下称"《股东会规则》"）等法律、法规和规范性文件以及 贵公司《公司章程》的有关规定，按照律师行业公认的业务标准、道德规范和勤 勉尽责精神，对本次股东大会的召集和召开程序、召集人和出席会议人员的资格、 表决程序和表决结果等重要事项进行见证，并出具本法律 ...

证券代码：688687 证券简称：凯因科技 公告编号：2025-016 北京凯因科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 20 日 （二） 股东大会召开的地点：北京市北京经济技术开发区荣京东街 6 号 3 号楼 会议室 本次会议由公司董事会召集，董事长周德胜先生主持，会议采取现场投票和 网络投票相结合的表决方式。本次股东大会的召集和召开程序、出席会议人员的 资格和召集人资格、会议的表决程序和表决结果均符合《中华人民共和国公司法》 及《北京凯因科技股份有限公司章程》的规定。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事7人，出席7人； 2、 公司在任监事3人，出席3人； 3、 公司董事会秘书王湛先生出席了本次会议,其他高级管理人员均列席了本次 会议。 二、 议案审议情况 （一） 非累积投票议案 1、 议案名称：《关于公司 2024 ...

广东信达律师事务所 股东大会法律意见书 深圳市福田区益田路 6001 号太平金融大厦 11、12 楼 邮政编码：518038 11/12/F, Tai Ping Finance Tower, 6001 Yitian Road, Futian District, Shenzhen, P. R. China 电话(Tel)：(0755)88265288 传真(Fax) ：(0755) 83265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：www.sundiallawfirm.com 广东信达律师事务所 关于北京凯因科技股份有限公司 2024 年年度股东大会的 法律意见书 广东信达律师事务所（以下简称"信达"）接受北京凯因科技股份有限公司 （下称"贵公司"）的委托，指派律师参加了贵公司 2024 年年度股东大会（下 称"本次股东大会"），并进行了必要的验证工作。 信达律师根据《中华人民共和国公司法》（下称"《公司法》"）、《上市 公司股东会规则》（下称"《股东会规则》"）等法律、法规和规范性文件以及 贵公司《公司章程》的有关规定，按照律师行业公认的业务标 ...

A股生物制品板块短线拉升，三生国健涨超10%，诺诚健华、荣昌生物、迈威生物、凯因科技、智翔金 泰等跟涨。 ...

法律意见书 关于 北京凯因科技股份有限公司 实施 2025 年员工持股计划相关事宜的 法律意见书 二〇二五年五月 中国深圳福田区益田路 6001 号太平金融大厦 11、12 楼邮编：518038 11&12/F, TaiPing Finance Tower, 6001 Yitian Road, Futian District, Shenzhen, P.R.CHINA 电话(Tel)：(0755)88265288 传真(Fax)：(0755)88265537 电子邮件（E-mail）：info@sundiallawfirm.com 网址（Website）：https://www.sundiallawfirm.com 法律意见书 广东信达律师事务所 关于北京凯因科技股份有限公司 实施 2025 年员工持股计划相关事宜的 法律意见书 信达持股字[2025]第 004 号 致：北京凯因科技股份有限公司 广东信达律师事务所（以下简称"信达"）接受北京凯因科技股份有限公司 （以下简称"凯因科技"或"公司"）委托，以特聘专项法律顾问的身份参与凯 因科技 2025 年员工持股计划项目。现信达根据《中华人民共和国公司法》《中华 ...

北京凯因科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 2024 年年度股东大会会议资料 目 录 | 2024 年年度股东大会会议须知 | | 3 | | | --- | --- | --- | --- | | 2024 年年度股东大会会议议程 | | 5 | | | 议案一：关于公司 | 2024 | 年度董事会工作报告的议案 8 | | | 议案二：关于公司 | 2024 | 年度监事会工作报告的议案 18 | | | 议案三：关于公司 | 2024 | 年年度报告及摘要的议案 24 | | | 议案四：关于公司 | 2024 | 年度财务决算报告及 2025 年度财务预算报告的议案 25 | | | 议案五：关于公司 | 2024 | 年度利润分配方案的议案 32 | | | 议案六：关于公司续聘 2025 | | 年度审计机构的议案 33 | | | 议案七：关于公司董事 2025 | | 年度薪酬方案的议案 34 | | | 议案八：关于公司监事 2025 | | 年度薪酬方案的议案 35 | | | 议案九：关于《公司 20 ...

Core Viewpoint - The company experienced a decline in revenue for 2024 due to the implementation of centralized procurement policies, but showed growth in net profit and is optimistic about future product approvals [2][3]. Group 1: Financial Performance - In 2024, the company achieved operating revenue of 1.23 billion, a year-on-year decrease of 12.87%. However, the net profit attributable to shareholders was 142 million, reflecting a year-on-year increase of 22.18%. The net profit excluding non-recurring items was 137 million, up 11.75% year-on-year [2]. - For Q1 2025, the company reported operating revenue of 232 million, a year-on-year increase of 8.90%. The net profit attributable to shareholders was 26 million, up 15.92%, while the net profit excluding non-recurring items was 24 million, an increase of 16.08% year-on-year [2]. Group 2: Impact of Centralized Procurement - The decline in revenue for 2024 was primarily due to the implementation of centralized procurement policies for products like Jinshuxi and Kaiyin Yisheng, which led to a decrease in sales prices across various regions. The initial phase of these policies also caused disruptions in the sales channels, impacting Q4 revenue [3]. Group 3: Future Product Development - The company is optimistic about the approval of its core product, KW-001 (Pegylated Interferon α-2 Injection), which successfully completed Phase III clinical trials in 2024 and has submitted a drug registration application. The company maintains a high level of investment in R&D and is accelerating the development of its pipeline [4]. - Other projects in the pipeline include KW-045 and KW-051, both of which have completed their respective clinical trial phases, and KW-053, which has received approval for clinical trials for the treatment of condyloma acuminatum [4].

Core Insights - The company reported a revenue of 1.23 billion in 2024, a year-on-year decrease of 12.87%, while the net profit attributable to shareholders was 142 million, an increase of 22.18% [1] - For Q1 2025, the company achieved a revenue of 232 million, a year-on-year increase of 8.90%, and a net profit of 26 million, up 15.92% [1] Revenue and Profit Analysis - The decline in 2024 revenue is attributed to the implementation of centralized procurement policies, which led to a decrease in sales prices for key products [2] - The transition phase of the sales model for Anboshi in 2024 also contributed to the revenue impact [2] Product Development and Future Outlook - The company is optimistic about the approval of its core product, KW-001 (Pegylated Interferon α-2 Injection), which completed Phase III clinical trials in 2024 and has submitted a drug registration application [2] - Other projects in the pipeline include KW-045 and KW-051, both of which have completed their respective clinical trial phases, and KW-053 has received approval for clinical trials [2] Profit Forecast and Valuation - The profit forecasts for 2025 and 2026 have been revised down to 171 million and 221 million respectively, reflecting an 11% reduction from previous estimates [3] - The company is recognized as a leading innovative pharmaceutical enterprise focused on viral and immune diseases, with several commercialized products entering a growth phase, maintaining a "buy" rating [3]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's revenue for 2024 is expected to decline by 12.87% to 1.23 billion yuan due to the implementation of centralized procurement policies, which have led to price reductions for key products [2][3] - The company anticipates the successful approval and market launch of its core product, KW-001 (long-acting interferon α-2 injection), in 2025, following the completion of Phase III clinical trials [2][3] - The report projects a recovery in revenue growth starting in 2025, with an estimated revenue of 1.35 billion yuan, reflecting a growth rate of 9.73% [3] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 1.23 billion yuan, a decrease of 12.87% year-on-year, while net profit attributable to shareholders was 142 million yuan, an increase of 22.18% [1][2] - For Q1 2025, the company reported a revenue of 232 million yuan, up 8.90% year-on-year, with a net profit of 26 million yuan, reflecting a growth of 15.92% [1][2] Profit Forecast and Valuation - The net profit forecasts for 2025 and 2026 have been revised down to 171 million yuan and 221 million yuan, respectively, representing an 11% reduction from previous estimates [3] - The estimated price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 28, 21, and 19 times, respectively [3] Research and Development - The company has maintained a high level of investment in research and development, with several projects in the pipeline, including KW-045 and KW-051, which have completed their respective clinical trials [2][3]